JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

Search

Madrigal Pharmaceuticals Inc

Abierto

SectorSanidad

416 -0.45

Resumen

Variación precio

24h

Actual

Mínimo

412.15

Máximo

420.57

Métricas clave

By Trading Economics

Ingresos

31M

-42M

Ventas

76M

213M

BPA

-1.9

Margen de beneficios

-19.869

Empleados

528

EBITDA

31M

-39M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+21.75% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

2.9B

9.8B

Apertura anterior

416.45

Cierre anterior

416

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

168 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 oct 2025, 22:47 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 oct 2025, 22:13 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 oct 2025, 21:20 UTC

Ganancias

Correction to IBM 3Q Sales Jump Article

22 oct 2025, 20:57 UTC

Ganancias

SAP Posts Higher 3Q Revenue, Operating Profit

22 oct 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 oct 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 oct 2025, 23:41 UTC

Charlas de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct 2025, 23:38 UTC

Charlas de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct 2025, 23:15 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 oct 2025, 22:28 UTC

Charlas de Mercado

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 oct 2025, 22:02 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 oct 2025, 21:59 UTC

Adquisiciones, fusiones, absorciones

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 oct 2025, 21:58 UTC

Adquisiciones, fusiones, absorciones

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 oct 2025, 21:57 UTC

Adquisiciones, fusiones, absorciones

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 oct 2025, 21:56 UTC

Adquisiciones, fusiones, absorciones

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 oct 2025, 21:47 UTC

Adquisiciones, fusiones, absorciones

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 oct 2025, 21:47 UTC

Ganancias

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct 2025, 21:47 UTC

Adquisiciones, fusiones, absorciones

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 oct 2025, 21:46 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 oct 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 oct 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 oct 2025, 21:28 UTC

Charlas de Mercado
Ganancias

Correction to Alcoa Tariff Market Talk

22 oct 2025, 21:25 UTC

Ganancias

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 oct 2025, 21:17 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 oct 2025, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

22 oct 2025, 20:59 UTC

Ganancias

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct 2025, 20:51 UTC

Ganancias

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 oct 2025, 20:44 UTC

Ganancias

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Comparación entre iguales

Cambio de precio

Madrigal Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

21.75% repunte

Estimación a 12 Meses

Media 506.43 USD  21.75%

Máximo 590 USD

Mínimo 266 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

14

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

263.2 / 277.1Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

168 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat